论文部分内容阅读
目的:通过研究恶性造血细胞中P-糖蛋白(P-gp)170的表达,为骨髓增生异常综合征(MDS)治疗提供P-gp 170低表达的体外细胞株模型。方法:用含0.1 mmol.L-1阿霉素的RPM I 1640分别培养MDS细胞株MUTZ-1和多药耐药(MDR)红白血病细胞株K562/A02。用MTT法检测细胞的增殖抑制作用,光镜和电镜技术分别观察与阿霉素共同培养后的MUTZ-1细胞和K562/A02细胞形态和超微结构,流式细胞仪分别测定MUTZ-1细胞和K562/A02细胞P-gp 170表达水平。结果:0.1 mmol.L-1阿霉素对MUTZ-1细胞增殖呈时间依赖性抑制作用,而对K562/A02细胞的增殖没有影响;MUTZ-1细胞出现典型的凋亡形态学改变,K562/A02细胞表面呈现出许多长的微绒毛和许多微孔;K562/A02细胞与MUTZ-1细胞相比高表达P-gp 170。结论:P-gp 170在恶性造血细胞中表达有显著性差异,P-gp 170低表达的MUTZ-1细胞株可用于MDS治疗的体外研究模型,P-gp 170高表达的K562/A02细胞株可用于MDR逆转的体外研究模型。
OBJECTIVE: To provide an in vitro cell line model for the treatment of myelodysplastic syndrome (MDS) with low expression of P-gp 170 by studying the expression of P-glycoprotein (P-gp) 170 in malignant hematopoietic cells. Methods: MDS cell line MUTZ-1 and multidrug-resistant (MDR) erythroleukemia cell line K562 / A02 were respectively cultured in RPMI 1640 containing 0.1 mmol·L-1 doxorubicin. Morphological and ultrastructural changes of MUTZ-1 cells and K562 / A02 cells after co-cultured with doxorubicin were observed respectively by MTT assay and MUTZ-1 cells assayed by flow cytometry And K562 / A02 cells P-gp 170 expression levels. Results: 0.1 mmol.L-1 doxorubicin inhibited the proliferation of MUTZ-1 cells in a time-dependent manner, but had no effect on the proliferation of K562 / A02 cells. MUTZ-1 cells showed typical morphological changes of apoptosis. K562 / A02 cell surface showed many long microvilli and many micropores; K562 / A02 cells highly expressed P-gp 170 compared to MUTZ-1 cells. Conclusion: The expression of P-gp 170 in malignant hematopoietic cells is significantly different. MUTZ-1 cell line with low expression of P-gp 170 can be used in in vitro model of MDS. K562 / A02 cell line with high expression of P-gp 170 In vitro model for MDR reversal.